(NASDAQ: CTMX) Cytomx Therapeutics's forecast annual revenue growth rate of -34.84% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 80.59%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.89%.
Cytomx Therapeutics's revenue in 2025 is $147,557,000.On average, 6 Wall Street analysts forecast CTMX's revenue for 2025 to be $7,560,745,479, with the lowest CTMX revenue forecast at $6,254,599,911, and the highest CTMX revenue forecast at $9,083,601,082. On average, 6 Wall Street analysts forecast CTMX's revenue for 2026 to be $4,017,842,758, with the lowest CTMX revenue forecast at $322,485,172, and the highest CTMX revenue forecast at $8,237,077,506.
In 2027, CTMX is forecast to generate $4,417,724,371 in revenue, with the lowest revenue forecast at $161,242,586 and the highest revenue forecast at $9,061,027,120.